Sugi Predict

Sugi Predict / Compounds / SCHEMBL16375225

SCHEMBL16375225

SCHEMBL16375225

CC(C)(C)OC(=O)CCNC(=O)[C@H](Cc1ccc(-c2ncc(-c3ccc(OCCC4CCCCC4)cc3)cn2)cc1)NC(=O)c1ccc(C(C)(C)C)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 5/20 0.42
▸ PSMB1 P20618 1/20 0.40
▸ PSMB8 P28062 1/20 0.40
▸ PSMB9 P28065 1/20 0.40
▸ PSMB5 P28074 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ KLKB1 P03952 1/20 0.39
▸ DDR1 Q08345 2/20 0.38
▸ MAPK14 Q16539 2/20 0.38
▸ DDR2 Q16832 2/20 0.38
▸ CTSL P07711 2/20 0.38
▸ KIFC1 Q9BW19 1/20 0.38
▸ PLG P00747 1/20 0.38
▸ GCGR P47871 2/20 0.37
▸ ACE P12821 1/20 0.37
▸ CHRNB2 P17787 1/20 0.37
▸ CHRNB4 P30926 1/20 0.37
▸ CHRNA3 P32297 1/20 0.37
▸ CHRNA4 P43681 1/20 0.37
▸ GRIN1 Q05586 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22384200 1.00 CTSS (0.42) CTSSPSMB1PSMB8PSMB9PSMB5
SCHEMBL16294799 0.92 CTSS (0.45) CTSSL3MBTL1KLKB1DDR1MAPK14
SCHEMBL16294798 0.92 CTSS (0.45) CTSSL3MBTL1KLKB1DDR1MAPK14
SCHEMBL22756160 0.90 PSMB5 (0.39) CTSSPSMB1PSMB8PSMB9PSMB5
SCHEMBL16306026 0.88 CTSS (0.37) CTSSPSMB1PSMB8PSMB9PSMB5
SCHEMBL22384055 0.88 L3MBTL1 (0.42) CTSSPSMB5L3MBTL1KLKB1CTSL
SCHEMBL16305639 0.86 L3MBTL1 (0.41) CTSSL3MBTL1KLKB1CTSLKIFC1
SCHEMBL22384056 0.86 L3MBTL1 (0.41) CTSSL3MBTL1KLKB1CTSLKIFC1
SCHEMBL16305975 0.86 CTSS (0.40) CTSSL3MBTL1KLKB1DDR1MAPK14
SCHEMBL16305727 0.85 KLKB1 (0.41) CTSSPSMB1PSMB8PSMB9PSMB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3008056-B1 NOVEL GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-12-09 — — EP disclosed
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 — — EP disclosed
US-10259823-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2019-04-16 — — US disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 — — US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 — — US disclosed
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2017-11-02 — — US disclosed
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2017-11-02 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
US-9598430-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-03-21 — — US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 — — US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 — — US disclosed
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-07-28 — — US disclosed
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-07-28 — — US disclosed
WO-2016094729-A1 GLP-1 RECEPTOR MODULATORS CELGENE INTERNATIONAL II SARL (CH) 2016-06-16 — — WO disclosed
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-01-08 — — US disclosed
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-01-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R CTSS 3233/4885PSMB1 2054/4885PSMB8 2499/4885
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R CTSS 3233/4885PSMB1 2054/4885PSMB8 2499/4885
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R CTSS 3233/4885PSMB1 2054/4885PSMB8 2499/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R CTSS 3233/4885PSMB1 2054/4885PSMB8 2499/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR CTSS 3308/4885PSMB1 2369/4885PSMB8 2789/4885
US-10259823-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR CTSS 3308/4885PSMB1 2369/4885PSMB8 2789/4885
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R CTSS 3233/4885PSMB1 2054/4885PSMB8 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback